OCA
JBIO

Octagon Capital Advisors’s Jade Biosciences JBIO Stock Holding History

Octagon Capital Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,298
Closed -$973K – 36
2024
Q3 		$973K Hold
13,298
– – 0.15% 37
2024
Q2 		$773K Buy
13,298
+1,764
+15% +$1.17M 0.12% 45
2024
Q1 		$11.9M Hold
11,534
– – 1.43% 21
2023
Q4 		$9.14M Sell
11,534
-2,677
-19% -$1.36M 1.46% 18
2023
Q3 		$6.75M Sell
14,211
-3,552
-20% -$1.92M 1.04% 21
2023
Q2 		$10.7M Hold
17,763
– – 1.48% 15
2023
Q1 		$12.5M Hold
17,763
– – 1.8% 12
2022
Q4 		$18.2M Buy
+17,763
New +$12.9M 2.84% 10

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM

Octagon Capital Advisors's JBIO Position: Q4 2024 in Review

Octagon Capital Advisors sold out of Jade Biosciences (JBIO) in Q4 2024, closing a stake of 13,298 shares — an estimated $973K sold.

Octagon Capital Advisors first reported a position in JBIO in Q4 2022 and held it in 8 quarters. The position peaked at $18.2M in Q4 2022. 78 funds tracked by Wall St. Rank hold JBIO as of Q4 2024.

  • Octagon Capital Advisors reported no remaining Jade Biosciences position as of Q4 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 13,298 Jade Biosciences shares in Q4 2024, an estimated $973K.
  • Octagon Capital Advisors first reported a position in Jade Biosciences in Q4 2022 and held it in 8 quarters.
  • Octagon Capital Advisors's Jade Biosciences position peaked at $18.2M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2024.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.